PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Biocompatibles UK Ltd / BTG Plc

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

BTG and Mirada Medical Announce CE Mark Certification for Simplicit90Y Dosimetry Software in Europe - BTG plc with Mirada Medical Ltd announced CE Mark certification for Simplicit90Y™ dosimetry software - / /
BTG and Mirada Medical Announce CE Mark Certification for Simplicit90Y Dosimetry Software in Europe


NewswireToday - /newswire/ - Farnham, Surrey, United Kingdom, 2016/10/14 - BTG plc with Mirada Medical Ltd announced CE Mark certification for Simplicit90Y™ dosimetry software - / / LSE: BTG

Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


BTG plc, an international specialist healthcare company, with Mirada Medical Ltd, a leading global brand in medical imaging software, today announced CE Mark certification for Simplicit90Y™ dosimetrysoftware, designed to optimise the planning of 90Y selective internal radiation therapy (SIRT) and facilitate personalised treatment for patients with liver cancer. CE Mark certification follows approval for Simplicit90Y™ in Canada.

BTG, in collaboration with Mirada Medical, have developed Simplicit90Y™ to be a customised, easy-to-use, dosimetry software developed for rapid 90Y SIRT workflow. Simplicit90Y™ provides digital processing, review and reporting of medical images with unique options for data display, quality control, image manipulation and quantification analysis. Together, these features allow for morestandardised and consistent dosimetry planning and post-treatment validation, and the ability to personalise treatment for each patient.

“Simplicit90Y™ represents an important advance in providing patients and healthcare providers with added value beyond our products and we are pleased it has received CE Mark certification,” commented Zillah Moore, Director Commercial Operations EMEA. “It will ensure 90Y therapies, such as TheraSphere®, can be specifically tailored to individual patient needs, facilitating personalised treatments. Simplicit90Y™ will help us offer interventional oncology teams more power to personalise and optimise 90Y SIRT for their patients. We’re delighted Simplicit90Y™ is now available for physicians to use.”

“Dosimetry can be a time intensive and complex process and Simplicit90Y™simplifies both dosimetry planning and post-treatment validation,” said Etienne Garin, MD, PhD, Chair professor of Nuclear Medicine, Cancer Institute, Centre Eugene Marquis Rennes, France. “Knowing you can use this intuitive software to help deliver a more personalised treatment for each patient, achieving the best dose of 90Y radiation to the tumour while minimising exposure to healthy tissue, gives physicians more confidence.”

Matthieu Leclerc-Chalvet, Mirada Medical, Managing Director commented,“We designed this software to simplify the dosimetry workflow for SIRTand enhance consistency and efficiency. Mirada Medical supports 90Y treatment quality by incorporating advanced image processing tools that facilitate the clinician’s use of multi-modal images to plan 90Y SIRT treatment. Leveraging combined expertise from across the industry helped meet both the physician’s and patient’s needs and Simplicit90Y™ is a clear demonstration of that success.”

BTG and Mirada Medical will be at the 29th Annual EANM Congress in Barcelona, Spain, 15th 19th of October, 2016. Information regarding Simplicit90Y™ will be available via the BTG booth (#62 & 76) and Mirada Medical booth (#65 & 66) in the main exhibition hall. For more information on Simplicit90Y™ please visit and register your interest.

About Simplicit90Y™
Simplicit90Y™ is a standalone software device intended for use by Nuclear Medicine (NM) or Radiology practitioners for display, processing and reporting of data, including planar scans (Static, Whole Body) and tomographic scans acquired by gamma cameras or PET scanners. Physicians can use the system for viewing and assessing image data for general clinical diagnostic purposes with additional features and optimised workflow for yttrium-90 (90Y) dosimetry.

About TheraSphere®
TheraSphere® 90Y glass microspheres are specifically engineered to carry far greater power than any other 90Y liver-directed cancer therapy.TheraSphere® works predominantly through radiation, with minimal embolic effect1 which allows the microspheres to lodge deeper inside the tumor, achieving a high absorbed dose. The result is a powerful, targeted and well-tolerated therapy that may lead to patients becoming eligible for curative therapies.

In the EU, Singapore, South Korea and Canada, TheraSphere® ( is approved for the treatment of hepatic neoplasia. TheraSphere® is commercially available in Hong Kong and Malaysia. In the US, TheraSphere® is approved under a Humanitarian Device Exemption (HDE) for use in radiation treatment or as a neoadjuvant to surgery or transplantation in patients with unresectable hepatocellular carcinoma (HCC) who can have placement of appropriately positioned hepatic arterial catheters. TheraSphere® is also indicated for HCC patients with partial or branch portal vein thrombosis/occlusion, when clinical evaluation warrants the treatment. The effectiveness of TheraSphere® for this use in the US has not been demonstrated.

About BTG Interventional Medicine
BTG Interventional Medicine ( is part of BTG plc, a growing international specialist healthcare company. As medicine moves from major surgery to minor procedure, from the systemic to the local, no company endeavors to do more than BTG Interventional Medicine to help doctors in their quest to see more, reach further and treat smarter. Our growing portfolio of Interventional Medicine products is designed to advance the treatment of cancer tumors, advanced emphysema, severe blood clots, and varicose veins.

About Mirada Medical Ltd
Mirada Medical ( is a leading international brand in medical imaging. The company develops advanced software applications which help healthcare professionals use medical images more effectively and efficiently to improve cancer care. Mirada’s products are used across diagnostic radiology, molecular imaging, radiation oncology, medical oncology, tumour board and elsewhere. Mirada Medical was originally spun out of the University of Oxford. The company’s technologies and products continue to be developed by their team of specialists, engineers and world-renowned scientists at Mirada’s world headquarters in Oxford, England.

Media Liaison: Jonathan Kearney
P: +44(0)20 8618 2755 / Mobile: +44(0)77 2592 5841

Mirada Medical Ltd: Annamaria Albano, Marketing Programmes Manager
P: +44(0)18 6526 1410 - E: Annamaria.albano[.]

Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


Written by / Agency / Source: Biocompatibles UK Ltd / BTG Plc


Availability: All Regions (Including Int'l)


Traffic Booster: [/] Quick Newswire Today Visibility Checker


Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

# # #

  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!

BTG and Mirada Medical Announce CE Mark Certification for Simplicit90Y Dosimetry Software in Europe

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

BTG Interventional Med. | Mirada Medical Ltd
Publisher Contact: Chris Sampson - 
+44(0)20 7575 1595 / +44(0)77 7325 1178 (mobile) chris.sampson[.]
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Biocompatibles UK Ltd / BTG Plc securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Read Latest Articles From Biocompatibles UK Ltd / BTG Plc / Company Profile

Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

MDxHealth and Exact Sciences Sign Collaboration Agreement
BD Advances Efforts to Combat Antimicrobial Resistance with Enhanced Diagnostic Solution Offering
First European Patients Treated with DC Bead LUMI™ Radiopaque Drug-Eluting Beads
FDA Approves Genentech’s Lucentis (Ranibizumab Injection) for Diabetic Retinopathy
Biopharmaceutical Analytical Instrumentation Market Garners Strong Opportunities from Double-digit Growth in Biosimilars Finds Frost & Sullivan
BD Completes Acquisition of Caesarea Medical Electronics
MDxHealth and Ghent University Ink Licensing and Collaboration Agreements to Develop Cancer Biomarker Visualization Technology
Ipsen Completes Acquisition of ONIVYDE® (irinotecan liposome injection) and Additional Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Breakthrough Therapy Designation for Rituxan® (Rituximab) in Pemphigus Vulgaris
MDxHealth Signs Agreement with Lab21 to Make SelectMDx Liquid Biopsy Test Available in the United Kingdom
Greenphire Drives Global Site Adoption of Clinical Trial Payment Solutions
Ipsen Announces MHRA Approval of New Indication for Decapeptyl® for the Treatment of Pre-menopausal Women with Early Stage Breast Cancer
SelectMDx Chosen by Michigan Medicine as Pre-biopsy Diagnostic Tool in Groundbreaking US Prostate Cancer Risk Clinic
BTG Announces CE Mark Certification for DC Bead LUMI™ - The First Commercially Available Radiopaque Drug-Eluting Bead
Sartorius to Acquire Real-time Live-cell Analysis Pioneer and Leader Essen BioScience

Boost Your Social Network
& Crowdfunding Campaigns

NewswireToday Celebrates 10 Years in Business



Visit  MagLar, Inc.

  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (